JAK Inhibitors Linked to Higher Cancer Risk Across IMIDs
JAK inhibitors are associated with a higher risk for malignancy than TNF inhibitors across immune-mediated inflammatory diseases, according to a meta-analysis. Medscape Medical News source https://www.medscape.com/viewarticle/jak-inhibitors-linked-higher-risk-cancer-than-tnf-inhibitors-2026a1000ok5?src=rss